- Home
- SUPV vs EVMN Comparison
SUPV vs EVMN Comparison
Compare SUPV & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SUPV | EVMN |
|---|---|---|
| Founded | 1887 | 2020 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 814.9M | 892.4M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | SUPV | EVMN |
|---|---|---|
| Price | $8.05 | $24.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $13.00 | ★ $44.17 |
| AVG Volume (30 Days) | ★ 872.1K | 303.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.32% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $97.93 | N/A |
| Revenue Next Year | $25.55 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.54 | $13.89 |
| 52 Week High | $17.02 | $33.20 |
Technical Indicators
Market Signals| Indicator | SUPV | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 33.72 | 51.41 |
| Support Level | $7.89 | $15.25 |
| Resistance Level | $8.30 | $33.20 |
| Average True Range (ATR) | 0.58 | 2.29 |
| MACD | -0.06 | -0.50 |
| Stochastic Oscillator | 7.19 | 43.20 |
Price Performance
Historical ComparisonAbout SUPV Grupo Supervielle S.A. each Representing five Class B shares
Grupo Supervielle SA offers financial products & services. The company's segments include Personal and Business Banking, Corporate Banking, Bank Treasury, Consumer Finance, Insurance, and Asset Management and other services. The company provides services to individuals, small businesses, middle-market companies, and large corporates in Argentina. The company also offers mutual fund services.
About EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.